SBIR Phase I: Early Diagnosis of the COVID-19 Cytokine Storm via Point-of-Care Antibody Profiling
- Funded by National Science Foundation (NSF)
- Total publications:0 publications
Grant number: 2036098
Grant search
Key facts
Disease
COVID-19Start & end year
20202021Known Financial Commitments (USD)
$256,000Funder
National Science Foundation (NSF)Principal Investigator
Anna SchibelResearch Location
United States of AmericaLead Research Institution
Electronic Bio SciencesResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Diagnostics
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to predict a patient's risk for developing an adverse and often lethal response to certain viral infections, such as COVID-19. This project proposes a fast and accurate test for the severity of COVID-19 infection. The proposed assay has the potential to enable early intervention and save lives. It can potentially be used for many other infections and public health hazards beyond COVID-19.
This Small Business Innovation Research (SBIR) Phase I project will produce a new technology capable of diagnosing immune response dysregulation to any infectious disease (e.g., SARS-CoV-2, dengue, influenza, hepatitis C, etc.) that progress through an antibody dependent enhancement (ADE) mechanism. While infection by the SARS-CoV-2 virus begins as a mild illness, some patients experience a sudden and rapid decline in health, precipitated by a massive release of pro-inflammatory cytokines, i.e., a "cytokine storm," Cytokine storms cause hyperinflammation of the lungs, which leads to acute respiratory distress syndrome (ARDS), the leading cause of COVID-19 mortality. Unfortunately, there is presently no test capable of predicting this event. This project aims to fill this medical technology gap via the development of a highly multiplexed, rapid, sensitive, disposable immunoassay specific to COVID-19 infections to be deployed at scale. The effort will include designing, building, and optimizing a prototype immunoassay based on nanopore technology innovations and analytically validating the developed technology against industry standards.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
This Small Business Innovation Research (SBIR) Phase I project will produce a new technology capable of diagnosing immune response dysregulation to any infectious disease (e.g., SARS-CoV-2, dengue, influenza, hepatitis C, etc.) that progress through an antibody dependent enhancement (ADE) mechanism. While infection by the SARS-CoV-2 virus begins as a mild illness, some patients experience a sudden and rapid decline in health, precipitated by a massive release of pro-inflammatory cytokines, i.e., a "cytokine storm," Cytokine storms cause hyperinflammation of the lungs, which leads to acute respiratory distress syndrome (ARDS), the leading cause of COVID-19 mortality. Unfortunately, there is presently no test capable of predicting this event. This project aims to fill this medical technology gap via the development of a highly multiplexed, rapid, sensitive, disposable immunoassay specific to COVID-19 infections to be deployed at scale. The effort will include designing, building, and optimizing a prototype immunoassay based on nanopore technology innovations and analytically validating the developed technology against industry standards.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.